The acceptance of three simultaneous vaccine injections recommended at 12 months of age

Jeffrey N Hanna, Ruth C Bullen, Debora E Andrews

Abstract

Since January 2003, vaccination with Meningococcal C conjugate vaccine (MenCCV) is recommended at 12 months of age, at the same time as the measles-mumps-rubella (MMR) and *Haemophilus influenzae* type b (Hib) vaccines. Most (83%) of a cohort of 751 children in north Queensland born in January 2003 received the three injectable vaccines simultaneously. Of the 122 children who had not received MenCCV with the other two vaccines, 88 (72%) had received it by 18 months of age. The median age of receipt of MenCCV in the children who had received the three vaccines simultaneously was 12.3 months, whereas the median age in the children who had not received it at the same time as the other two vaccines was 14.0 months. This study suggests that non-simultaneous vaccination puts children at-risk of receiving MenCCV late, or not at all, and has implications for the introduction of universal infant pneumococcal vaccination program, starting in January 2005. *Commun Dis Intell* 2004;28:493–496.

Keywords: multiple vaccine injections, simultaneous vaccinations, meningococcal C conjugate vaccine

Introduction

The meningococcal C conjugate vaccine (MenCCV) was introduced into the Australian Standard Vaccination Schedule (ASVS) in January 2003. The vaccine is recommended to be administered at 12 months of age, at the same time as the administration of the first dose of measles-mumps-rubella (MMR) and the third dose of *Haemophilus influenzae* type b (Hib) vaccine.

Since mid-2001, with the introduction of the seven-valent pneumococcal conjugate vaccine (7vPCV) it has been recommended that Indigenous children receive three vaccine injections at two and four months of age. However, the introduction of MenCCV is the first time that three simultaneous vaccine injections are recommended for all Australian children.

Little is known about the acceptability of three simultaneous injectable vaccines to Australian vaccine providers and parents of young children. If three simultaneous injections are considered ‘unacceptable’ they might be ‘split’, with two vaccines given at a first visit and the third at a second visit some time later. If this occurs, it is likely that the most recently introduced vaccine (in this case MenCCV) would be the vaccine given later and there is the possibility that the return visit might either occur late or not occur at all.

The aims of this study were to determine the percentage of a cohort of children in north Queensland that had received the three vaccines simultaneously, and to describe some of the characteristics of the children that did not receive the three vaccines simultaneously.

Methods

The vaccination records of all children born in January 2003, who were resident in north Queensland when they were eligible for the three vaccines (i.e. from 12 months of age onwards), were extracted from the state-wide immunisation register (VIVAS). For each child the age when the three vaccines were administered was recorded, as was the child’s Indigenous status.

Six vaccines—including three doses of Japanese encephalitis (JE) vaccine—are recommended on three visits in the 12th month of life for children on the outer islands of the Torres Strait. MenCCV is recommended for these children with the second dose of JE vaccine (one week after MMR and the
first dose of JE vaccine). Therefore any outer island child who either had MenCCV simultaneously with the MMR and the first dose of JE vaccine, or (as recommended) simultaneously with the second dose of JE vaccine, was defined for the purpose of this study as having had the three vaccines simultaneously.

In cases where the Indigenous status of a child was not recorded, it was assumed that the child was Indigenous if he/she had received both BCG at birth and 7vPCV. The last known vaccine provider was contacted for any further clarification of a child’s Indigenous status.

If one or more of the three vaccines was not recorded as having been given to any child, the relevant vaccine provider was contacted and asked for further details. If the vaccine(s) had not been given, the provider was requested to recall the child for vaccination, and if that occurred to ensure that the relevant details were forwarded for entry onto VIVAS. If none of the three vaccines had been given, the relevant Public Health Nursing Officer was informed and requested to attempt to locate the child and, if successful, to request a vaccine provider to vaccinate the child.

The vaccination record extraction for the study commenced in March 2004, and was concluded at the end of July. By this time all the study children would have reached 18 months of age.

Results

The study cohort consisted of 751 children, 165 (22%) of whom were Indigenous children. Seventeen of the Indigenous children were from the outer Torres Strait islands, only eight of whom had received the three injectable vaccines simultaneously (as defined in Methods above).

Four children, all of whom were Indigenous, had not received any of the three injectable vaccines by 18 months of age. Two children (both Indigenous) who were very overdue for various infant vaccines had had four simultaneous injectable vaccines including MMR and Hib but not MenCCV, as part of catch-up schedules, and the parent of another child had refused MMR (but not MenCCV or Hib) for her child. These latter three children therefore could not have had the three recommended vaccines—MMR, Hib and MenCCV—administered simultaneously.

Five children had received privately-purchased MenCCV in age-appropriate schedules in the first year of life. It was assumed that these children would otherwise have had MenCCV simultaneously with the MMR and Hib vaccines, which had indeed been given at the same time. Another seven children had been given a third dose of Hib vaccine at about six months of age, but all had received a fourth dose simultaneously with MMR and MenCCV.

Altogether, 99 per cent of the 751 children had received MMR, 98.5 per cent Hib, and 94.5 per cent MenCCV by 18 months of age. Very similar percentages of Indigenous (93%) and non-Indigenous children (95%) had received MenCCV by 18 months of age.

Altogether, 622 (83%) of the children had received the three injectable vaccines simultaneously. Virtually the same percentage of Indigenous (82%) and non-Indigenous (83%) children received the vaccines simultaneously.

Of the 122 children who had not received MenCCV simultaneously with the other two vaccines, 88 (72%) had received it by 18 months of age. The median age of receipt of MenCCV in the children who had received the three vaccines simultaneously was 12.3 months, whereas the median age of receipt of MenCCV in the children who had not received it at the same time as the other two vaccines was 14.0 months. The cumulative uptake of the three vaccines by age is shown in the Figure.

The vaccine providers who gave MMR to the 122 children who did not receive the three vaccines simultaneously were general practitioners (90; 74%), Queensland Health community health staff (29; 24%) and other providers (3; 2%).

Figure. The cumulative percentage uptake of measles-mumps-rubella, Haemophilus influenzae type b and Meningococcal C conjugate vaccines in the study cohort, North Queensland, by month January to July 2004

The vaccine providers who gave MMR to the 122 children who did not receive the three vaccines simultaneously were general practitioners (90; 74%), Queensland Health community health staff (29; 24%) and other providers (3; 2%).
Discussion

A survey of parental and general practitioner attitudes to multiple vaccine injections in New South Wales in 1997 found that 'only 54 per cent of parents and 28 per cent of GPs said they would allow three injections to be given at one visit'. However, this current study has demonstrated not only that most (83%) children received the three vaccines simultaneously, but also that the multiple vaccine recommendation (introduced in January 2003) had been rapidly accepted and implemented. This difference between the hypothetical attitudes and the practical realities is very similar to that seen in the United States of America prior to, and after, the introduction of inactivated polio vaccine (IPV) not combined with any other antigens.4-6

There are two possible reasons that might explain this difference between attitude and practice. Firstly, two (MMR and Hib) of the three vaccines were already relatively well known to parents and vaccine providers, and the other (MenCCV) was for the prevention of a disease that has attracted considerable adverse publicity in Australia in recent years. Secondly, attitudinal surveys indicated that many parents were likely to accept a recommendation of multiple simultaneous injections for their children from a vaccine provider,3,4 and clearly most providers are comfortable not only with recommending multiple vaccine injections but also administering them.

However, it is of considerable concern that only 72 per cent of the 122 children who did not receive the three vaccines simultaneously had received the MenCCV by 18 months of age. Indeed, this figure is likely to be higher than expected for two reasons: a letter from the Australian Government’s Chief Health Officer was sent in June 2004 to all parents of young children who had (apparently) not received MenCCV informing them of the availability of this vaccine free for their children, and the study process itself involved directly contacting vaccine providers and informing them to recall children who had not yet received the vaccine. Without these two reminders, it is likely that even fewer children would have received MenCCV by 18 months of age.

This study has demonstrated that non-simultaneous vaccination puts children at-risk of receiving MenCCV late, or not at all. It also confirms that it is the most recently recommended vaccine, in this case MenCCV, is the most likely to be administered separately from the other vaccines, so as to avoid more than two injections at the same time.

The findings of this study have implications for the introduction of universal infant 7vPCV, to commence in January 2005. This change to the ASVS will mean that three vaccine injections (in Queensland: DTPa-hepB, Hib, 7vPCV) are recommended for all children at two and four months of age. The exception would be if an infant’s parents were prepared to purchase the hexavalent DTPa-hepB-IPV-Hib vaccine, to be administered simultaneously with 7vPCV at two, four and six months of age. This option is not considered suitable for Indigenous children.

Severe invasive pneumococcal disease can occur early in life, even in apparently low-risk infants.7 For example, in 21 cases of pneumococcal meningitis in low-risk non-Indigenous infants in north Queensland, the median age of these children was 11 (range 4–24) months of age. Two children developed the meningitis before six months of age, and 10 (48%) had onsets before eight months of age. Therefore, it is imperative that there not be any unnecessary delays in administering 7vPCV if the vaccine is to have an optimal impact in preventing invasive pneumococcal disease.

The recommendations to administer MenCCV simultaneously at 12 months of age, and 7vPCV simultaneously at two and four months of age were made after consideration of evidence concerning adverse events and immune responses following the simultaneous administration of the relevant vaccines.8 Vaccine providers, in particular general practitioners, need to be reassured that the available evidence indicates that these vaccines, when given simultaneously as recommended, are safe and effective. Quite simply, the most important factor influencing parents to agree to multiple injectable vaccines for their children is a confident and positive recommendation from the vaccine provider.

Acknowledgements

We wish to thank Brad McCulloch, Kathy Lort-Phillips and Brigitte Dostie for their assistance with this study. We also wish to thank all the vaccine service providers who provided us with information relevant to the study.

References


A family cluster of serogroup C meningococcal disease

*Megan K Young,1 Bradley J McCall,2 Helen V Smith,3 David Looke4*

The Brisbane Southside Public Health Unit, received notification of a case of probable meningococcal septicaemia in a 22-year-old female on the 25th May 2004. Onset of illness was the 23rd May. Symptoms included lethargy, malaise and headache. On presentation, the patient was febrile and hypotensive, with an extensive purpuric rash. The patient responded to appropriate treatment and made a full recovery complicated by post infectious polyarthritis. The diagnosis was confirmed with positive blood cultures for *Neisseria meningitidis*. Five household contacts received prophylactic antibiotics on the 25th May, including the case’s 2-year-old child. Other (non-household) contacts were provided with information after confirmation of the diagnosis on the 26th May.

On the 27th May 2004, the public health unit received notification that *Neisseria meningitidis* had been isolated from an eye swab. The swab was taken on the 22nd May from the right eye of the case’s 2-year-old child. Investigation revealed that this child had developed purulent conjunctivitis on the 21st May after an upper respiratory illness of approximately one week’s duration.

The parent case had been interstate for the duration of the child’s conjunctival symptoms. The child had been taken by carers to the GP on the 22nd May in response to increasing respiratory symptoms. The GP prescribed Cefaclor (Ceclor®) for the child’s respiratory infection and chloramphenicol eye drops for the conjunctivitis. At the time of notification, the child was well and had completed a two day course of rifampicin in addition to the chloramphenicol eye drops. The course of Cefaclor (Ceclor®) had yet to be completed. The child was up to date with vaccinations including the conjugate meningococcal C vaccination that had been administered six months earlier.

Two additional close contacts were identified in relation to the child case. Both had received prophylaxis at the time of the parent case’s diagnosis, although this had not been initially recommended by public health. Two other social contacts were given information.

Isolates from the parent and child were confirmed as *Neisseria meningitidis* serogroup C 2a, p 1.5. The blood isolate from the parent case and the con-

1. Public Health Registrar, Brisbane Southside Public Health Unit, Brisbane, Queensland
2. Public Health Physician, Brisbane Southside Public Health Unit, Brisbane, Queensland
3. Public Health Microbiology, Queensland Health Scientific Services, Coopers Plains, Queensland
4. Infectious Disease Physician, Princess Alexandra Hospital, Woolloongabba, Queensland

Corresponding author: Dr Megan K Young, Public Health Registrar, Brisbane Southside Public Health Unit, Brisbane, PO Box 333, Archerfield, Queensland 4108. Telephone: +61 7 3000 9148. Facsimile +61 7 3000 9130. Email: megan_young@qld.health.gov.au